October 17, 2005 -- Predix Pharma is scheduled to make its IPO this week, offering 5 million shares, with $10 to $12 being the talk price. Predix Pharma specializes in the development of small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. Its lead drug candidate is an agonist of 5-HT1A, indicated for General Anxiety Disorder. We look at this drug, the company, and its finances...
